<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633191</url>
  </required_header>
  <id_info>
    <org_study_id>Pseud-IgY-1</org_study_id>
    <nct_id>NCT00633191</nct_id>
  </id_info>
  <brief_title>Anti-pseudomonas IgY to Prevent Infections in Cystic Fibrosis</brief_title>
  <acronym>PseudIgY</acronym>
  <official_title>Post Marketing Study of Anti-pseudomonas IgY in Prevention of Recurrence of Pseudomonas Aeruginosa Infections Infections in Cystic Fibrosis (CF) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunsystem AB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunsystem AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Daily gargling with specific avian antibodies against Pseudomonas aeruginosa will
      prevent infections with this bacteria in patients with Cystic fibrosis (CF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Anti-pseudomonas IgY&quot; is prepared from eggs of hens that have been vaccinated with
      Pseudomonas aeruginosa. The hens farm is under veterinary control according to Swedish rules.
      The drug is prepared with a water dilution method according to GMP standards (approved by
      Swedish MPA). Patients with CF who are intermittently but not chronically infected with P.
      aeruginosa get a short course of antibiotics to eradicate the bacteria. Thereafter they start
      to gargle with a solution of &quot;anti-pseudomonas IgY&quot; every night to prevent a new infection.
      Preliminary results have shown that it takes a significantly longer time to get a new
      infection and that the patients get fewer infections than control patients. In addition,
      results tentatively indicate that: patients have not got any new opportunistic bacteria or
      fungi (B. Cepacia, S. Maltophilia, A. Xylosoxidans, atypical Mycobacteria, Aspergillus
      Fumigatus); that use of antibiotics is greatly diminished; that the lung functions and
      nutritional conditions are maintained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum culture positive for Pseudomonas aeruginosa</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Infection</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <arm_group>
    <arm_group_label>Anti-pseudomonas IgY gargle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Gargles with anti-pseudomonas IgY every night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-pseudomonas IgY gargle</intervention_name>
    <description>Gargle (solution), &gt; 5FKU, every night after toothbrushing, life-long</description>
    <arm_group_label>Anti-pseudomonas IgY gargle</arm_group_label>
    <other_name>oral immunotherapy</other_name>
    <other_name>Yolk antiboidies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of cystic fibrosis

          -  Colonized with Pseudomonas aeruginosa

          -  informed consent

        Exclusion Criteria:

          -  Egg allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annika Hollsing, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala Children´s University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cystic fibrosis centre,Children´s University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Carlander D, Kollberg H, Larsson A. Retention of specific yolk IgY in the human oral cavity. BioDrugs. 2002;16(6):433-7.</citation>
    <PMID>12463766</PMID>
  </reference>
  <reference>
    <citation>Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003 Jun;35(6):433-40.</citation>
    <PMID>12746939</PMID>
  </reference>
  <reference>
    <citation>Nilsson E, Kollberg H, Johannesson M, Wejåker PE, Carlander D, Larsson A. More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J Med Food. 2007 Jun;10(2):375-8.</citation>
    <PMID>17651078</PMID>
  </reference>
  <reference>
    <citation>Nilsson E, Larsson A, Olesen HV, Wejåker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol. 2008 Sep;43(9):892-9. doi: 10.1002/ppul.20875.</citation>
    <PMID>18680179</PMID>
  </reference>
  <reference>
    <citation>Nilsson E, Amini A, Wretlind B, Larsson A. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):75-80. Epub 2007 Jun 2.</citation>
    <PMID>17581799</PMID>
  </reference>
  <reference>
    <citation>Nilsson E, Hanrieder J, Bergquist J, Larsson A. Proteomic characterization of IgY preparations purified with a water dilution method. J Agric Food Chem. 2008 Dec 24;56(24):11638-42. doi: 10.1021/jf802626t.</citation>
    <PMID>19053374</PMID>
  </reference>
  <reference>
    <citation>Nilsson E, Stålberg J, Larsson A. IgY stability in eggs stored at room temperature or at +4°C. Br Poult Sci. 2012;53(1):42-6. doi: 10.1080/00071668.2011.646951.</citation>
    <PMID>22404803</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2008</study_first_submitted>
  <study_first_submitted_qc>March 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2008</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Prevention</keyword>
  <keyword>Infection</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Gargle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

